Drug Profile
LBP-BPI
Alternative Names: BPI-LBP; NCY 118Latest Information Update: 24 Aug 2009
Price :
$50
*
At a glance
- Originator Incyte Corporation
- Class Amino acids; Antibacterials; Antidotes
- Mechanism of Action Cell membrane permeability enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Gram-negative infections; Septic shock
Most Recent Events
- 03 Aug 2005 Discontinued - Preclinical for Septic shock in USA (IV)
- 10 Nov 2004 LBP-BPI has been licensed to Zephyr Sciences worldwide
- 14 Jul 1998 No-Development-Reported for Septic shock in USA (IV)